Claudia Lefeuvre‐Plesse

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Élisa Gobbini, Monia Ezzalfani, Véronique Dièras et al. · European Journal of Cancer · 2018 · 274 citations

Prognostic Evaluation, Breast Oncology, Medicine +9

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

Élise Deluche, Alison Antoine, Thomas Bachelot et al. · European Journal of Cancer · 2020 · 180 citations

Metastatic Breast Cancer, Breast Oncology, Cancer Epidemiology +9

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 157 citations

Medicine, Metronomic Therapy, Gynecology +8

Genomics to select treatment for patients with metastatic breast cancer

Fabrice André, Thomas Filleron, Maud Kamal et al. · Nature · 2022 · 157 citations

Metastatic Breast Cancer, Breast Oncology, Tumor Heterogeneity +9